A Single Arm Study of Traditional Chinese Medicine for Plasma Cell Mastitis

• Status: Recruiting
• Trial end date: 2023-03-31
• Target enrollment: 0
• Participant gender: Female

Summary

This is a single-center, single-arm, open-label trial evaluating the efficacy and safety of traditional Chinese medicine for plasma cell mastitis.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Shengjing Hospital

Criteria

Inclusion Criteria:

1. Meet the diagnostic criteria for plasma cell mastitis.

2. Women aged > 20 years and ≤ 60 years.

3. Karnofsky Performance Status (KPS) Scale score ≥ 70.

4. Volunteers to participate in the study, provision of signed informed consent, good compliance and willingness to cooperate with follow-ups.

Exclusion Criteria:

1. Pregnant and lactating women; fertile women who provide positive results of baseline pregnancy test; women of childbearing age who are unwilling to take effective contraceptive measures during the whole study period.

2. Patients with serious underlying diseases, such as diabetes, cardiovascular and cerebrovascular diseases, liver, kidney and hematopoietic system diseases.

3. Allergic constitution, such as a history of allergies to two or more drugs or foods; or those who are known to be allergic to the ingredients of the drugs used in this trial.

4. Recent use of antidepressants and other psychotropic drugs.

5. Hormone and immunosuppressive therapy were used one month before enrollment.